Absynth Biologics discovers and develops vaccines and antibodies to prevent and treat bacterial infections; based on a platform for identifying novel protein antigen targets that harness the immune system and that use a dual-action mechanism:

  • Direct antibacterial activity by antibody-mediated inhibitory effect; and 
  • Engagement of classic immune effector functions to eliminate the bacteria


Founded by Fusion IP (now part of IP Group plc; www.ipgroupplc.com) Absynth has established a vaccine pipeline targeting the pathogens Staphylococcus aureus, Clostridium difficile and Streptococcus pyogenes. There are no marketed vaccines for any of these pathogens and a limited number of candidates in clinic trials. Consequently, each of Absynth’s pipeline programmes addresses an unmet market need with peak sales estimated to be >$1 billion p.a.

Bacterial infections remain a major cause of death, with microbial drug resistance being a significant contributing factor. Antibiotic resistance now is a global problem, which world health leaders have described as “. a catastrophic threat” to people worldwide. It is now broadly accepted that a multi-pronged approach is needed to address the impact of antibiotic resistance including new antibiotics, vaccines and antibodies, alongside improved practices to control disease transmission.

For further information, please browse this website or e-mail us at This email address is being protected from spambots. You need JavaScript enabled to view it.

Paid for by direct debit